Evidence map›Paper›PMID 34721419›Full record

ArticleFrontiers in immunology2021

MALT1-Dependent Cleavage of HOIL1 Modulates Canonical NF-κB Signaling and Inflammatory Responsiveness.

Shan-Yu Fung, Henry Y Lu, Mehul Sharma, Ashish A Sharma, Aabida Saferali, Alicia Jia, Libin Abraham, Theo Klein, Michael R Gold, Luigi D Noterangelo and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Human germline biallelic loss-of-functionJournal of human immunity · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. MALT1 substrate cleavage: what is it good for?Frontiers in immunology · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Shan-Yu FungDepartment of Pediatrics, British Columbia Children's Hospital and The University of British Columbia, Vancouver, BC, Canada.
Henry Y LuDepartment of Pediatrics, British Columbia Children's Hospital and The University of British Columbia, Vancouver, BC, Canada.
Mehul SharmaDepartment of Pediatrics, British Columbia Children's Hospital and The University of British Columbia, Vancouver, BC, Canada.
Ashish A SharmaDepartment of Pathology, Case Western Reserve University, Cleveland, OH, United States.
Aabida SaferaliChanning Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Alicia JiaDepartment of Pediatrics, British Columbia Children's Hospital and The University of British Columbia, Vancouver, BC, Canada.
Libin AbrahamDepartment of Microbiology and Immunology, The University of British Columbia, Vancouver, BC, Canada.
Theo KleinDepartment of Analytical Solutions, Ducares/Triskelion BV, Utrecht, Netherlands.
Michael R GoldDepartment of Microbiology and Immunology, The University of British Columbia, Vancouver, BC, Canada.
Luigi D NoterangeloLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Christopher M OverallDepartment of Biochemistry and Molecular Biology, Department of Oral Biological and Medical Science, Center for Blood Research, The University of British Columbia, Vancouver, BC, Canada.
Stuart E TurveyDepartment of Pediatrics, British Columbia Children's Hospital and The University of British Columbia, Vancouver, BC, Canada.
University of British Columbia · CABrigham and Women's Hospital · USCase Western Reserve University · USNational Institutes of Health · USTianjin Medical University · CN

Funding

CIHR FDN148408
6 · The paper itself

Abstract

Nuclear factor kappa B (NF-κB) is a critical transcription factor involved in regulating cell activation, inflammation, and survival. The linear ubiquitin chain assembly complex (LUBAC) which consists of HOIL1, HOIP, and SHARPIN, catalyzes the linear ubiquitination of target proteins-a post-translational modification that is essential for NF-κB activation. Human germline pathogenic variants that dysregulate linear ubiquitination and NF-κB signaling are associated with immunodeficiency and/or autoinflammation including dermatitis, recurrent fevers, systemic inflammation and enteropathy. We previously identified MALT1 paracaspase as a novel negative regulator of LUBAC by proteolytic cleavage of HOIL1. To directly investigate the impact of HOIL1 cleavage activity on the inflammatory response, we employed a stable transduction system to express and directly compare non-cleavable HOIL1 with wild-type HOIL1 in primary HOIL1-deficient patient skin fibroblasts. We discovered that non-cleavable HOIL1 resulted in enhanced NF-κB signaling in response to innate stimuli. Transcriptomics revealed enrichment of inflammation and proinflammatory cytokine-related pathways after stimulation. Multiplexed cytokine assays confirmed a 'hyperinflammatory' phenotype in these cells. This work highlights the physiological importance of MALT1-dependent cleavage and modulation of HOIL1 on NF-κB signaling and inflammation, provides a mechanism for the autoinflammation observed in MALT1-deficient patients, and will inform the development of therapeutics that target MALT1 paracaspase and LUBAC function in treating autoinflammatory skin diseases.

Indexed as

CytokinesFibroblastsHumansInflammationMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinNF-kappa BSignal TransductionTranscription FactorsUbiquitin-Protein LigasesCytokinesMALT1 protein, humanMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinNF-kappa BRBCK1 protein, humanTranscription FactorsUbiquitin-Protein LigasesHOIL1 cleavageLUBACMALT1NF-κBregulation of inflammation

Identifiers

PMID34721419
PMCPMC8552041
OpenAlexW3205056778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.